Randa G. Hanna-Sawires
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Randa G. Hanna-Sawires has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alexander Hamming
Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands
1 shared publicationAlexander L. Vahrmeijer
Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands
1 shared publicationBert A. Bonsing
Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands
1 shared publication- Bert A. Bonsing
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
1 shared publication F.A. Klok
Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Centre, Leiden, the Netherlands
1 shared publication- Hans F. A. Vasen
Department of Clinical Genetics, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark
1 shared publication
Latest Publications
- Open Access
- 1 November 2021
- Published by Elsevier in Thrombosis Research
- Vol. 207, 134-139
Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer
- 1 November 2021
- Published by Elsevier in Thrombosis Research
- Vol. 207, 134-139
Open AccessIncidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer
- Open Access
- 6 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2655
Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is known as a highly aggressive malignant disease. Prognosis for patients is notoriously poor, despite improvements in surgical techniques and new (neo)adjuvant chemotherapy regimens. Early detection of PDAC may increase the overall survival. It is furthermore foreseen that precision medicine will provide improved prognostic stratification and prediction of therapeutic response. In this review, omics-based discovery efforts are presented that aim for novel diagnostic and prognostic biomarkers of PDAC. For this purpose, we systematically evaluated the literature published between 1999 and 2020 with a focus on protein- and protein-glycosylation biomarkers in pancreatic cancer patients. Besides genomic and transcriptomic approaches, mass spectrometry (MS)-based proteomics and glycomics of blood- and tissue-derived samples from PDAC patients have yielded new candidates with biomarker potential. However, for reasons discussed in this review, the validation and clinical translation of these candidate markers has not been successful. Consequently, there has been a change of mindset from initial efforts to identify new unimarkers into the current hypothesis that a combination of biomarkers better suits a diagnostic or prognostic panel. With continuing development of current research methods and available techniques combined with careful study designs, new biomarkers could contribute to improved detection, prognosis, and prediction of pancreatic cancer.
- 6 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2655
Open AccessClinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is known as a highly aggressive malignant disease. Prognosis for patients is notoriously poor, despite improvements in surgical techniques and new (neo)adjuvant chemotherapy regimens. Early detection of PDAC may increase the overall survival. It is furthermore foreseen that precision medicine will provide improved prognostic stratification and prediction of therapeutic response. In this review, omics-based discovery efforts are presented that aim for novel diagnostic and prognostic biomarkers of PDAC. For this purpose, we systematically evaluated the literature published between 1999 and 2020 with a focus on protein- and protein-glycosylation biomarkers in pancreatic cancer patients. Besides genomic and transcriptomic approaches, mass spectrometry (MS)-based proteomics and glycomics of blood- and tissue-derived samples from PDAC patients have yielded new candidates with biomarker potential. However, for reasons discussed in this review, the validation and clinical translation of these candidate markers has not been successful. Consequently, there has been a change of mindset from initial efforts to identify new unimarkers into the current hypothesis that a combination of biomarkers better suits a diagnostic or prognostic panel. With continuing development of current research methods and available techniques combined with careful study designs, new biomarkers could contribute to improved detection, prognosis, and prediction of pancreatic cancer.